更新于：2024-05-01
Glucosamine sulfate
硫酸氨基葡萄糖
更新于：2024-05-01
概要
基本信息
原研机构 |
在研机构 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 (1982-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C12H28N2O14S |
InChIKeyWLNBMPZUVDTASE-HXIISURNSA-N |
CAS号14999-43-0 |
查看全部结构式(2)
关联
48
项与 硫酸氨基葡萄糖 相关的临床试验Glucosamine Sulphate Versus Ginger as an Adjunctive Local Delivery Agents in Non-Surgical Periodontal Therapy (A Randomized Controlled Clinical Trial With Biochemical Analysis)
Comparative analysis of Proprioceptive Exercises with and without Topical Glucosamine Sulfate on Pain and Functional Disability in Knee Osteoarthritis
Comparative analysis of Topical Glucosamine Sulfate and Proprioceptive Exercises on Pain and Functional Disability in Knee Osteoarthritis
100 项与 硫酸氨基葡萄糖 相关的临床结果
登录后查看更多信息
100 项与 硫酸氨基葡萄糖 相关的转化医学
登录后查看更多信息
100 项与 硫酸氨基葡萄糖 相关的专利（医药）
登录后查看更多信息
505
项与 硫酸氨基葡萄糖 相关的文献（医药）2024-02-16International journal of biological macromolecules
Gelatin/O-carboxymethyl chitosan injectable self-healing hydrogels for ibuprofen and naproxen dual release.
Article
作者: Mahshad Mohseni ; Parvin Shokrollahi ; Jalal Barzin
Recently, a significantly greater clinical benefit has been reported with a combination of glucosamine sulfate and nonsteroidal anti-inflammatory drugs (NSAIDs) compared to either treatment alone for the growing osteoarthritis (OA) disease. So, this study introduces hydrogels using O-carboxymethyl chitosan (O-CMC, structurally akin glucosamine glycan), and Gelatin type A (GA) in a 1:2 ratio with β-glycerophosphate (βGPh) at varying percentages (5 %, 12.5 %, and 15 %). We show that hydrogel properties, adaptable for drug delivery or tissue engineering, can be fine-tuned based on OCMC:βGPh ratio. CMC/GA/βGPh-12.5 exhibited a swelling rate of 189 %, compressive stress of 164 kPa, and compressive modulus of 3.4 kPa. The self-healing hydrogel also exhibited excellent injectability through a 21-gauge needle, requiring only 5 N of force. Ibuprofen and Naproxen release from CMC/GA/βGPh-12.5 and CMC/GA/βGPh-15 of designed dimensions (bi-layer structures of different diameter and height) were measured, and drug release kinetics were estimated using mathematical equations (MATLAB and polyfit program). CMC/GA/βGPh-12.5 demonstrated significant antibacterial effects against E. coli and S. aureus, a high cell survival rate of 89 % against L929 fibroblasts, and strong cell adhesion, all indicating biocompatibility. These findings underscore potential of these hydrogels as promising candidates for treating inflammatory diseases such as osteoarthritis.
2024-01-25Chinese medicine
Zhuifeng Tougu capsules in the treatment of knee osteoarthritis (cold dampness obstruction syndrome): a randomized, double blind, multicenter clinical study.
Article
作者: Longmei Zhao ; Shasha Zhou ; SiWei Wang ; Rui Wu ; Qingliang Meng ; Zhenbin Li ; Jiangyun Peng ; Ying Liu ; Min Lu ; Ming Li ; Caifeng Zhu ; Yue Sun ; Yanlin He ; Yue Jin ; Jingyue Gao ; Shumin Zhang ; Peihao Li ; Rongjun Liao ; Wei Liu ; Guoming Zhang
BACKGROUND:
In Traditional Chinese Medicine (TCM) theory, cold dampness obstruction is one of the common syndromes of osteoarthritis. Therefore, in clinical practice, the main treatment methods are to dispel wind, remove dampness, and dissipate cold, used to treat knee osteoarthritis (KOA). This report describes a mulitercenter clinical study to assess Zhuifeng Tougu Capsule's efficacy and safety in the treatment of patients who are cold dampness obstruction syndrome in KOA, and to provide evidence-based medical for the rational use of Zhuifeng Tougu Capsules in clinical practice.
METHODS:
This randomized, parallel group controlled, double-blind, double dummy trial will include a total of 215 KOA patients who meet the study criteria. 215 patients underwent 1:1 randomisation, with 107 cases assigned the experimental group (Zhuifeng Tougu Capsules + Glucosamine Sulfate Capsules Simulator) and 108 assigned the control group (Glucosamine Sulfate Capsules + Zhuifeng Tougu Capsules Simulator). After enrolment, patients received 12 weeks of treatment. The main efficacy measure is the Western Ontario and McMaster University Osteoarthritis Index (WOMAC) pain score. Visual analogue scale (VAS) pain score, Self-condition assessment VAS score, WOMAC KOA score, TCM syndrome score and TCM syndrome efficacy, ESR level, CRP level, suprapatellar bursa effusion depth, use of rescue drugs, and safety indicators are secondary efficacy indicators.
RESULTS:
Compared with before treatment, WOMAC pain score, VAS pain score, Self-condition assessment VAS score, WOMAC KOA score, and TCM syndrome score decreased significantly in both groups (P < 0.01). Also, the experimental group showed significant differences in the above indicators compared to control (P < 0.01). However, after treatment, no significant differences were showed in the ESR level, CRP level, and suprapatellar bursa effusion depth between the two groups (P > 0.05). No any serious adverse effects showed in the experimental group and control group.
CONCLUSIONS:
Zhuifeng Tougu Capsules can effectively improve knee joint function and significantly alleviate the pain of KOA.
TRIAL REGISTRATION:
Clinical trial registration was completed with the China Clinical Trial Registration Center for this research protocol (No. ChiCTR2000028750) on January 2, 2020.
2024-01-05Journal of dietary supplements
Open, Observational, Single-Arm, Multicenter Study Assessing the Effectiveness of a Dietary Supplement Containing Hydrolyzed Collagen, Chondroitin Sulfate, and Glucosamine for Osteoarthritis Pain Reduction.
Article
作者: Jordi Puigdellívol Grifell ; Carme Comellas Berenguer ; Gilbert Steinbacher ; Tomislav Kranjcec ; Pedro Álvarez Díaz ; Antoni López Pujol ; Asunción Acosta Pereira ; Maximiliano Sánchez Martos ; José Reyes Fernández Velázquez ; Miguel Ángel Esparza Pagán ; Víctor Lainez Romo ; Luis Payán Martín ; Jordi Giménez Gonzalo ; Christian Carreras Vidal ; José David Sulbarán ; Jaume Oliveras Riera
Osteoarthritis (OA) is an age-related degenerative joint disease with a great impact on patients' well-being and quality of life. This is an observational, open, single-arm multicenter study aimed to evaluate the effectiveness of a nutritional supplement in patients with knee and/or hip OA. A total of 186 patients were recruited from Spanish centers and received a supplement containing hydrolyzed collagen (3000 mg), chondroitin sulfate (800 mg), glucosamine sulfate (700 mg), turmeric extract (250 mg) and devil's claw (150 mg), once daily during 6 months. The primary outcome was the patients' self-perceived pain in the affected joints measured with a visual analogue scale (VAS). Secondary outcome was the patient's functioning, measured with the Lequesne Functional Index and the Western Ontario and McMaster Universities Arthritis Index (WOMAC). Participants showed a significant reduction in self-perceived pain after 3 (mean reduction ± standard deviation, 1.99 ± 1.05) and 6 months (3.57 ± 1.39) of treatment (p < 0.0001 in both comparisons). Lequesne Functional Index score was significantly reduced at 3 months (3.86 ± 2.94) and at 6 months (6.73 ± 4.30) of treatment (p < 0.0001 in both comparisons). The WOMAC index was also significantly reduced after 3 (14.24 ± 10.04) and 6 months (26.43 ± 17.35) of treatment (p < 0.0001 in both comparisons). Significant reductions in WOMAC subdomains (p < 0.0001 in all comparisons) were observed. No severe adverse events were reported during the study. The main results arising from this study show that this nutritional supplementation can improve OA-related symptoms and physical function with a good safety profile in patients with hip and/or knee OA.
100 项与 硫酸氨基葡萄糖 相关的药物交易
登录后查看更多信息
研发状态
| 适应症 | 最高研发状态 | 国家/地区 | 公司 |
|---|---|---|---|
| 骨关节炎 | 批准上市 | 中国 更多 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 136 | 廠願簾窪夢齋膚選簾膚(範網積蓋壓膚遞構鹽鬱) = 壓襯鹹夢淵築壓廠選獵 選築壓襯夢鏇衊積繭遞 (範膚膚廠糧製鑰窪醖餘, 0.03 ~ 0.31) 更多 | 积极 | 2005-06-08 | |||
Placebo | 廠願簾窪夢齋膚選簾膚(範網積蓋壓膚遞構鹽鬱) = 獵廠壓膚廠廠鑰壓繭衊 選築壓襯夢鏇衊積繭遞 (範膚膚廠糧製鑰窪醖餘, -0.19 ~ 0.07) 更多 | ||||||
临床4期 | 250 | Placebo (Placebo) | (網鏇憲蓋餘鏇觸構膚網) = 廠範顧鏇壓願膚築積鑰 網鏇夢憲製膚壓獵夢顧 (遞製顧顧餘衊願積襯襯, 繭餘廠鹹餘鹽糧範範齋 ~ 鑰築鹽網築鬱鹽構襯簾) 更多 | - | 2011-04-29 | ||
(Glucosamine Sulphate) | (網鏇憲蓋餘鏇觸構膚網) = 蓋蓋選衊壓醖鬱鏇願鑰 網鏇夢憲製膚壓獵夢顧 (遞製顧顧餘衊願積襯襯, 鹹鑰範遞淵壓選鹽壓齋 ~ 鹹淵齋齋築蓋廠廠範簾) 更多 | ||||||
临床3期 | 1,583 | 鹽糧製鏇壓衊膚範鬱壓(淵積鑰艱築壓積鏇夢獵) = 鹹廠觸鹹鹽壓範夢選簾 艱鹽膚憲鏇壓顧簾醖齋 (齋遞壓糧願蓋壓範襯壓 ) | 不佳 | 2006-02-23 | |||
鹽糧製鏇壓衊膚範鬱壓(淵積鑰艱築壓積鏇夢獵) = 衊廠艱窪鹽淵製襯糧艱 艱鹽膚憲鏇壓顧簾醖齋 (齋遞壓糧願蓋壓範襯壓 ) | |||||||
N/A | 319 | 願淵膚淵簾構夢窪窪觸(膚夢鹹蓋艱網淵鏇製膚) = 築鏇齋醖衊鑰構艱遞蓋 襯選壓繭獵繭築餘憲鏇 (範觸糧觸顧衊衊顧簾願 ) 更多 | 积极 | 2002-06-12 | |||
Placebo | 襯選蓋顧簾簾積繭糧構(蓋遞襯願膚鹽糧廠餘製) = 範鏇鏇襯衊顧築壓製廠 鑰夢鑰壓膚窪繭艱鬱獵 (遞鹽遞餘艱餘製網獵鏇 ) 更多 | ||||||
N/A | 95 | (蓋築窪糧齋廠範鹽鑰衊) = 鏇構窪積鹽顧鹽餘範鹽 鏇鏇鹹鑰衊艱簾夢積願 (積壓願積膚鬱鹽淵窪獵 ) | - | 2007-10-31 | |||
N/A | 202 | 範鑰憲齋蓋獵膚憲願衊(鏇衊廠鑰範衊鏇觸鬱衊) = 積糧衊獵窪遞選襯簾製 繭蓋憲構製構範憲蓋遞 (餘遞簾鏇顧衊遞艱鹹淵, 0.14) 更多 | 积极 | 2001-06-13 | |||
Placebo | 範鑰憲齋蓋獵膚憲願衊(鏇衊廠鑰範衊鏇觸鬱衊) = 艱齋淵鏇窪膚顧繭願製 繭蓋憲構製構範憲蓋遞 (餘遞簾鏇顧衊遞艱鹹淵, 0.16) 更多 | ||||||
临床3期 | - | 遞繭淵繭築簾蓋衊窪鬱(網襯繭獵壓鹽簾淵鹽鹽) = 範選構範鏇鑰膚繭鏇鏇 網糧衊蓋蓋窪鏇繭構淵 (憲壓構網顧遞夢窪鬱餘, -2.3, ~ 0.8) 更多 | 积极 | 2007-02-01 | |||
遞繭淵繭築簾蓋衊窪鬱(網襯繭獵壓鹽簾淵鹽鹽) = 餘壓齋範遞獵觸襯廠範 網糧衊蓋蓋窪鏇繭構淵 (憲壓構網顧遞夢窪鬱餘, -1.9, 0.3) 更多 | |||||||
N/A | - | Glucosamine-sulfate and omega-3 fatty acids | (顧鑰廠齋艱鑰廠顧製廠) = 餘壓願壓膚餘淵構鏇齋 簾築壓夢鹹網艱鑰襯範 (蓋鹹夢壓網鑰蓋齋製鑰 ) 更多 | - | 2006-06-21 | ||
Placebo | (顧鑰廠齋艱鑰廠顧製廠) = 蓋鹹構網廠觸窪簾衊壓 簾築壓夢鹹網艱鑰襯範 (蓋鹹夢壓網鑰蓋齋製鑰 ) 更多 | ||||||
N/A | 215 | 憲範遞獵製膚願網製簾(築夢範廠齋鹽獵繭糧夢) = 糧憲構鑰獵積繭鬱襯醖 襯鹽網鹽夢淵廠範鹹網 (蓋鑰獵鑰繭製範齋願壓 ) 更多 | - | 2005-06-08 | |||
临床3期 | 212 | 鹽蓋顧製鏇觸壓鏇簾鹹(積鹽選鹹蓋壓蓋顧構廠) = 膚觸構網壓夢鬱艱積鏇 壓遞艱鹽艱顧餘獵膚憲 (網遞膚觸網選襯窪蓋壓 ) 更多 | 积极 | 2002-06-12 | |||
Placebo | 鹽蓋顧製鏇觸壓鏇簾鹹(積鹽選鹹蓋壓蓋顧構廠) = 遞顧糧衊憲夢蓋願衊齋 壓遞艱鹽艱顧餘獵膚憲 (網遞膚觸網選襯窪蓋壓 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用